Presentation is loading. Please wait.

Presentation is loading. Please wait.

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB.

Similar presentations


Presentation on theme: "Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB."— Presentation transcript:

1 Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB (HER2-Positive) and CALGB (Triple-Negative)  David W. Ollila, MD, FACS, Constance T. Cirrincione, MS, Donald A. Berry, PhD, Lisa A. Carey, MD, William M. Sikov, MD, Clifford A. Hudis, MD, Eric P. Winer, MD, Mehra Golshan, MD, FACS  Journal of the American College of Surgeons  Volume 224, Issue 4, Pages (April 2017) DOI: /j.jamcollsurg Copyright © 2017 American College of Surgeons Terms and Conditions

2 Figure 1 C40601 schema. AC, adjuvant chemotherapy; BCT, breast-conserving therapy; HER2, human epidermal growth factor receptor-2; T, weekly paclitaxel; H, trastuzumab; L, lapatinib. ∗Excluding clinical T4d tumors. Journal of the American College of Surgeons  , DOI: ( /j.jamcollsurg ) Copyright © 2017 American College of Surgeons Terms and Conditions

3 Figure 2 C40603 Schema. AUC, area under the curve; BCT, breast-conserving therapy; ddAC, dose-dense doxorubicin and cyclophosphamide. ∗Treatment decision made at the discretion of breast oncology team. Journal of the American College of Surgeons  , DOI: ( /j.jamcollsurg ) Copyright © 2017 American College of Surgeons Terms and Conditions


Download ppt "Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB."

Similar presentations


Ads by Google